Retrospective Analysis of Methotrexate Elimination When Coadministered With Levetiracetam by Reeves, David et al.
Butler University
Digital Commons @ Butler University
Scholarship and Professional Work – COPHS College of Pharmacy & Health Sciences
2016
Retrospective Analysis of Methotrexate Elimination











Follow this and additional works at: http://digitalcommons.butler.edu/cophs_papers
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital Commons @ Butler University. It has
been accepted for inclusion in Scholarship and Professional Work – COPHS by an authorized administrator of Digital Commons @ Butler University.
For more information, please contact fgaede@butler.edu.
Recommended Citation
Reeves, David; DiDominick, Sarah; Finn, Suzanne; Kim, Hyeon Jin; and Shake, Amanda, "Retrospective Analysis of Methotrexate




© The Author(s) 2016






High-dose methotrexate protocols are utilized in the treat-
ment of various cancers. Methotrexate is an antimetabolite 
that interferes with DNA synthesis by inhibiting dihydrofo-
late reductase, preventing the synthesis of purine nucleotides 
and thymidylate, and causing the subsequent death of cancer 
cells.1 It was the first agent to provide a cure for cancer as 
monotherapy, and it has continued to remain a cornerstone 
of various anticancer regimens throughout the years.2 
Unfortunately, methotrexate is also well known for its many 
drug interactions, which require careful management during 
therapy. The majority of methotrexate undergoes renal elim-
ination and can be influenced by renal function, urinary 
pH, and coadministration of medication competing for elim-
ination.3,4 Methotrexate also undergoes hepatic metabolism 
via cytochrome P-450 isoenzymes. Because of these issues 
with methotrexate pharmacokinetics, serum methotrexate 
concentrations are routinely monitored at 24, 48, and 72 
hours after the start of the methotrexate infusion with stan-
dard goal concentrations being ≤10 to 20 µmol/L at 24 hours 
(depending on duration of infusion), ≤1 µmol/L at 48 hours, 
and ≤0.1 µmol/L at 72 hours.3,5
Many antiepileptic agents utilize the same metabolic 
pathways as methotrexate, resulting in increased or decreased 
serum drug concentrations of one or the other.6 These inter-
actions could be detrimental to patient outcomes if not prop-
erly managed because they could result in increased toxicity, 
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Abstract
Background: Delayed elimination of methotrexate was previously reported in 2 patients receiving concomitant levetiracetam. 
Objective: To explore the potential interaction between methotrexate and levetiracetam in patients receiving high-dose 
methotrexate. Methods: This retrospective study reviewed the records of 81 adults receiving 280 cycles of methotrexate to 
determine the effects of levetiracetam on methotrexate elimination. Institutional review board approval was obtained. Results: 
Levetiracetam was administered in 33 (12%) cycles of methotrexate. Patients receiving levetiracetam had significantly lower 
24-hour methotrexate concentrations compared with those not receiving levetiracetam (2.91 vs 7.37 µmol/L, P = 0.005). 
Despite this difference, concentrations at 48 and 72 hours were similar between groups. Times to nontoxic methotrexate 
concentration (<0.1 µmol/L) were the same regardless of the presence of levetiracetam. The frequency of delayed elimination 
at 24, 48, and 72 hours was similar in both groups as was the frequency of delayed elimination at any time point. Cox 
regression demonstrated that levetiracetam was not a significant predictor of time to nontoxic methotrexate concentration 
(P = 0.796; HR = 1.058; 95% CI = 0.692-1.617), and logistic regression demonstrated that levetiracetam was not a significant 
predictor of delayed elimination at any time point. Levetiracetam use was similar between groups when comparing patients 
experiencing delayed elimination at any time point with those without delayed elimination (13% vs 10%, respectively, P = 
0.527). Conclusion: This study does not support the previous reports of a significant interaction between levetiracetam 
and methotrexate. A clinically significant interaction is unlikely in those without additional risk factors for delayed elimination.
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loss of seizure control, or decreased efficacy of the oncologi-
cal agent. Of particular concern is that interactions resulting 
in delayed methotrexate elimination may result in substan-
tial increases in potentially life-threatening toxicity, includ-
ing myelosuppression, mucositis, hepatotoxicity, and 
nephrotoxicity. Although it is best practice to avoid drug-
drug interactions, scenarios arise in which this is not always 
feasible.
Levetiracetam has become one of the preferred antiepi-
leptic agents used in patients with malignancies because 
of its limited potential for drug interactions.6 Historically, 
no drug-drug interaction between methotrexate and leveti-
racetam had been identified; however, 2 cases in which 
levetiracetam appears to cause a delay in the elimination 
of methotrexate have recently been published.7,8 Given the 
seriousness of any drug interaction with methotrexate, a 
retrospective study was completed to explore the possibil-




A retrospective chart review was performed on qualifying 
patients admitted between January 1, 2008, and August 1, 
2014, to a community teaching hospital. Adult patients at 
least 18 years old with an oncological diagnosis, who 
received at least 1 treatment of high-dose methotrexate 
(≥1000 mg/m2 intravenously [IV] over 3-4 hours or ≥800 
mg/m2 IV over 22-24 hours) were included in the study. 
Patients receiving multiple cycles of high dose methotrex-
ate were included in the study multiple times (once for each 
cycle). Patients were excluded from the study if they were 
pregnant or if methotrexate serum concentrations were not 
monitored. Potential participants were identified via the 
hospital’s electronic medical record system. The study 
design was reviewed and approved by the local institutional 
review board.
Data Collection
Electronic medical records were followed until plasma con-
centrations of methotrexate were nontoxic (≤0.1 µmol/L). 
Baseline characteristics, including demographic data, were 
gathered for all patients. Additionally, factors related to 
methotrexate administration and elimination, such as leu-
covorin use, presence of pleural effusion or ascites, use of 
urinary alkalinization, urine pH, alanine transaminase 
(ALT), aspartate transaminase (AST), baseline serum cre-
atinine, and methotrexate dose and infusion time were col-
lected. The Cockroft-Gault formula was used to estimate 
creatinine clearance.9 The coadministration of the following 
medications with the potential to interact with methotrexate 
elimination was noted: dantrolene, cephalosporins, aspirin, 
penicillins, sulfamethoxazole/trimethoprim, nonsteroidal 
anti-inflammatory drugs, and probenecid. Methotrexate 
concentrations were routinely monitored at 24, 48, and 72 
hours per hospital protocol. Patients with concentrations 
>0.1 µmol/L at 72 hours were routinely monitored daily, 
thereafter. The dose and schedule of levetiracetam were 
also noted.
End Points
The primary end point of the study was to determine 
whether coadministration of levetiracetam with metho-
trexate resulted in more instances of delayed elimination 
of methotrexate at any time point after administration 
when compared with patients who did not receive leveti-
racetam. Delayed elimination was defined as plasma 
methotrexate concentrations of >10 µmol/L at 24 hours if 
receiving bolus infusion methotrexate (ie, over 3-4 hours) 
or >20 µmol/L at 24 hours if receiving infusional metho-
trexate (ie, over 22-24 hours), >1 µmol/L at 48 hours, and 
>0.1 µmol/L at 72 hours. Secondary end points included a 
comparison of the proportion with delayed elimination at 
24, 48, and 72 hours; time to nontoxic methotrexate con-
centrations (<0.1 µmol/L); and a comparison of leveti-
racetam use among those with and without delayed 
elimination.
Statistical Analysis
Patient baseline characteristics were compared using χ2, 
Fisher’s exact, and Mann-Whitney U tests as appropriate. 
Analyses were completed on the entire study population as 
well as a subgroup of those receiving bolus methotrexate 
dosing to account for the differing 24-hour goals in those 
receiving bolus and infusional methotrexate (≤10 and ≤20 
µmol/L, respectively) and the fact that all patients receiving 
levetiracetam received bolus infusions. Binary logistic 
regression was utilized to evaluate the primary end point: 
delayed elimination at any time point. The following vari-
ables were included: baseline creatinine clearance, number 
of interacting medications, baseline AST, baseline ALT, and 
use of levetiracetam. Cox regression was utilized to evalu-
ate if levetiracetam was a significant predictor of time to 
nontoxic methotrexate concentrations, with the following 
variables included: baseline creatinine clearance, number of 
interacting medications, baseline AST, baseline ALT, and 
use of levetiracetam. Delayed elimination at 24, 48, and 72 
hours was compared via the Mann-Whitney U test, and 
levetiracetam use among those with and without delayed 
elimination was compared using the χ2 test. Data were ana-
lyzed using IBM SPSS Statistics for Windows, version 22 
(IBM Corp, Armonk, NY). A P value <0.05 was considered 
to be statistically significant.
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Results
Patient Characteristics
A total of 81 patients were identified and included, which 
represented 280 unique cycles of high-dose methotrexate. 
Levetiracetam was administered concurrently in 13 patients 
receiving a total of 33 cycles. Based on the number of 
patients, the study had 90% power to detect a 20% increase 
in the incidence of delayed elimination at any time point 
after administration. Baseline characteristics were well bal-
anced among the 2 groups, except for more cycles occur-
ring in slightly younger males in the group not receiving 
levetiracetam (Table 1). Additional differences in baseline 
characteristics of the entire population included baseline 
ALT and differences in methotrexate dosing because those 
receiving levetiracetam were likely to receive higher doses 
via a bolus infusion, which is consistent with the fact that 
the majority of the patients in the levetiracetam group had 
central nervous system malignancies. When the subgroup 
of cycles that utilized bolus infusions (≤4 hours in duration) 
was analyzed, it represented 59% of the methotrexate cycles 
(n = 166), and the baseline characteristics largely mirrored 
the entire population (Table 1). Disparities in methotrexate 
dosing between groups that were present in the entire popu-
lation were not present in the subgroup receiving bolus 
infusions. Levetiracetam dosing ranged from 500 mg daily 
to 1500 mg twice daily, with the majority receiving 500 mg 
twice daily, and all patients were either receiving levetirace-
tam prior to admission or stabilized on it prior to the start of 
methotrexate.
Supportive Management of Methotrexate 
Therapy
No differences were observed in the supportive care patients 
received in either the entire population or those receiving 
bolus infusions only. All patients received urinary alkalini-
zation and leucovorin rescue. Urine pH was 7 or higher in at 
least 96% of patients at 24, 48, and 72 hours after the start 
of the methotrexate infusion, and there were no differences 
Table 1. Baseline Characteristics.
Entire Population  
(n = 280)
Population Receiving Bolus Infusions 
(n = 166)
 
No LEV  
(n = 247) LEV (n = 33) P
No LEV  
(n = 133)
LEV  
(n = 33) P
Baseline characteristic  
 Male, n (%) 175 (71) 14 (42) 0.001 83 (62) 14 (42) 0.037
 Age, years, median (IQR) 52 (24) 57 (21) 0.003 54 (23) 57 (21) 0.004
 Body surface area, m2, median (IQR) 1.99 (0.36) 1.92 (0.57) 0.267 2.0 (0.37) 1.92 (0.57) 0.352
 Baseline creatinine clearance, mL/min, median (IQR) 91 (55) 89 (57) 0.301 82 (44) 89 (57) 0.711
 Baseline AST, U/L, median (IQR) 20 (15) 23 (8) 0.382 19 (16) 23 (8) 0.247
 Baseline ALT, U/L, median (IQR) 39 (21) 53 (22) 0.003 39 (36) 53 (22) 0.034
Diagnosis, n (%)  
 ALL 30 (12) 2 (2)  
 Burkitt’s lymphoma 41 (17) 2 (2)  
 CNS lymphoma 93 (38) 28 (85) 85 (64) 28 (85)  
 Leptomeningeal carcinomatosis 1 (<1) 1 (<1)  
 Mantle cell lymphoma 16 (7) 1 (<1)  
 NHL 33 (13) 2 (6) 23 (17) 2 (6)  
 NHL (testicular) 3 (1)  
 Osteosarcoma 17 (7) 3 (9) 17 (13) 3 (9)  
 T-cell lymphoma 13 (5) 2 (2)  
Total methotrexate dose, mg, median (IQR) 6000 (5100) 6800 (1895) 0.012 7000 (1700) 6800 (1895) 0.362
Long methotrexate infusion time (22-24 hours), n (%) 114 (46) 0 (0) <0.001  
Number of interacting medications, n (%) 0.931  
 0 199 (81) 27 (82) 108 (81) 27 (82)  
 1 37 (15) 5 (15) 19 (14) 5 (15)  
 2 11 (4) 1 (3) 6 (5) 1 (3)  
Pleural effusion, n (%) 1 (<1) 0 (0) 1.0 0 (0) 0 (0) 1
Ascites, n (%) 1 (<1) 0 (0) 1.0 1 (<1) 0 (0) 1
Abbreviations: ALL, acute lymphoblastic leukemia; ALT, alanine transaminase; AST, aspartate transaminase; CNS, central nervous system; IQR, 
interquartile range; LEV, levetiracetam; NHL, non-Hodgkin’s lymphoma.
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Table 2. Methotrexate Management and Monitoring.
Creatinine Clearance, mg/dL; median 
(IQR)
Urine pH ≥7, n (Percentage of Those With 
Result Available)
Entire population
Time after start of MTX infusion (hours) 24 48 72 24 48 72
No LEV Number with result available 184 191 150 223 236 177
Result 86 (57) 86 (63) 81 (58) 213 (96) 231 (98) 170 (96)
LEV Number with result available 30 30 22 33 33 24
Result 84 (49) 85 (47) 66 (54) 33 (100) 32 (97) 24 (100)
P value 0.568 0.278 0.232 0.369 0.548 1.0
Bolus infusion subgroup
No LEV Number with result available 110 104 83 129 127 102
 Result 82 (43) 82 (42) 78 (61) 125 (97) 127 (100) 102 (100)
LEV Number with result available 30 30 22 33 33 24
 Result 84 (49) 85 (47) 66 (54) 33 (100) 32 (97) 24 (100)
P value 0.571 0.909 0.389 0.583 0.206 1.0
Abbreviations: IQR, interquartile range; LEV, levetiracetam; MTX, methotrexate.
between groups in the proportion of patients with a pH ≥7 
(Table 2). Renal function, as represented by creatinine 
clearance, was also similar between groups at 24, 48, and 72 
hours after the start of the methotrexate infusion. These 
characteristics were similar in the population receiving 
bolus infusions (Table 2).
Methotrexate Concentrations and Elimination
In the entire population, methotrexate concentrations were 
similar at 48 and 72 hours after the start of methotrexate; 
however, median concentrations were higher at 24 hours in 
those not receiving levetiracetam (7.37 vs 2.91 µmol/L, P = 
0.005; Table 3). Despite this difference in concentrations at 
24 hours, there was no difference in the proportion of 
patients with delayed elimination at 24, 48, or 72 hours after 
the start of methotrexate, nor was there a difference in the 
proportion of patients experiencing delayed elimination at 
any time point. Logistic regression demonstrated that the 
only significant predictor of delayed elimination at any time 
point was baseline creatinine clearance (P = 0.012), whereas 
all other parameters were nonsignificant, including receipt 
of levetiracetam (P = 0.887). Median time to a nontoxic 
methotrexate concentration (methotrexate concentration < 
0.1 µmol/L) was also similar among groups (72 hours in 
those receiving no levetiracetam vs 78 hours in those receiv-
ing levetiracetam, P = 0.229). When data were analyzed 
utilizing Cox regression, receipt of levetiracetam was not a 
significant predictor of time to nontoxic methotrexate con-
centrations (P = 0.796; HR = 1.058; 95% CI = 0.692-1.617; 
Figure 1). The only significant predictor was baseline cre-
atinine clearance (P = 0.017; HR = 1.004; 95% 
CI = 1.001-1.008).
In the population receiving only bolus infusions, the dif-
ference in the median 24-hour methotrexate concentration 
observed in the entire population was not present (4.06 
µmol/L in those receiving no levetiracetam vs 2.91 in those 
receiving levetiracetam; P = 0.864; Table 3). All other 
parameters were similar to the entire population, including 
the proportion of those with delayed elimination and the 
median time to nontoxic methotrexate concentrations (Table 
3). Logistic regression was also similar, in that baseline cre-
atinine clearance was the only significant predictor of 
delayed elimination at any time (P < 0.001). Likewise, Cox 
regression in this population demonstrated that levetirace-
tam was not a significant predictor of time to nontoxic 
methotrexate concentration (P = 0.342; HR = 1.258; 95% 
CI = 0.784-2.019). Similar to the entire population, baseline 
creatinine clearance was the only significant predictor of 
time to nontoxic concentration in this subgroup (P = 0.014; 
HR = 1.008; 95% CI = 1.002-1.014).
Analysis of Levetiracetam Use in Those With/
Without Delayed Methotrexate Elimination
In addition to comparing those receiving levetiracetam with 
those not receiving the medication, data were also com-
pared based on the presence or absence of delayed metho-
trexate elimination (Table 4). Patients experiencing delayed 
methotrexate elimination tended to be older (49 vs 56 years 
old in the entire population, P = 0.003; 49 vs 57 years old in 
those receiving bolus infusions, P = 0.005). In those receiv-
ing bolus infusions, patients experiencing delayed elimina-
tion had a lower baseline creatinine clearance (101 vs 76 
mL/min, P < 0.001) and a lower body surface area (2.03 vs 
1.98 m2, P = 0.012). Moreover, in the entire population, 
patients experiencing delayed elimination received higher 
doses of methotrexate (3500 vs 3000 mg/m2, P = 0.002). 
The number of patients receiving levetiracetam in the group 
experiencing delayed elimination was similar to that in the 
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group not experiencing delayed elimination, as was the 
number of other interacting medications received by 
patients (Table 4).
Discussion
Methotrexate is an essential component in several cancer 
regimens, including in those patients with primary central 
nervous system lymphoma, who often require treatment for 
seizures. Levetiracetam for the treatment and prevention of 
seizures in those receiving chemotherapy has been utilized 
largely because of the relative lack of drug interactions com-
pared with other antiepileptic medications, such as phenyt-
oin. However, 2 case reports have called into question the 
safety of this combination. In the first case report, a 15-year-
old male patient with B-cell acute lymphoblastic leukemia 
experienced methotrexate toxicity when it was administered 
at a dose of 5 g/m2 concomitantly with levetiracetam.7 The 
patient had no risk factors for methotrexate toxicity; how-
ever, during his third infusion of high-dose methotrexate, 
after starting oral levetiracetam 7.5 mg/kg twice daily, he 
experienced elevated methotrexate concentrations, hyper-
tension, renal failure, and uncontrollable vomiting. The 
patient required treatment with carboxypeptidase G2 for 
the elevated methotrexate concentrations and renal failure. 
The second case reported in the literature included a 46-year-
old male patient receiving methotrexate 12 g/m2 for relapsed 
osteosarcoma.8 Prior to his second cycle of methotrexate, he 
was started on levetiracetam to control seizures caused by 
brain metastases. Although methotrexate elimination was 
slightly delayed during cycle 1 (time to methotrexate con-
centration <0.1 µmol/L = 90 hours), it was delayed even fur-
ther during cycles 2 to 4, during which levetiracetam was 
concomitantly administered (time to methotrexate concen-
tration <0.1 µmol/L = 106-144 hours). During cycle 5, loraz-
epam was substituted for levetiracetam, and methotrexate 
elimination was similar to that in cycle 1 (time to methotrex-
ate concentration <0.1 µmol/L = 95 hours).
The mechanism by which levetiracetam is thought to 
delay methotrexate elimination is not confirmed, but it may 
be related to the significant renal clearance of both medica-
tions. Methotrexate is cleared via glomerular filtration and 
active tubular secretion, as is the metabolite of levetirace-
tam (ucbL057).8 The excretion of both methotrexate and 
Table 3. Methotrexate Concentrations and Elimination.a
Methotrexate Concentration, µmol/L, 
Median (IQR) Delayed Elimination, n (%)
Delayed Elimination at 
Any Time, n (%)
Time to Methotrexate Concentration 
<0.1 µmol/L, hours, median (IQR)
Time after start of MTX infusion 
(hours)
24 48 72 24 48 72  
Entire population
No LEV Number with 
results available
219 247 228  
 Result 7.37 (15.78) 0.24 (0.57) 0.07 (0.16) 56 (23) 34 (14) 145 (59) 174 (70) 72 (29)
LEV Number with 
results available
33 33 31  
 Result 2.91 (7.71) 0.33 (0.66) 0.11 (0.19) 4 (12) 6 (18) 23 (70) 25 (76) 78 (48)
P value 0.005 0.771 0.896 0.095 0.496 0.344 0.527 0.229
Bolus infusion subgroup
No LEV Number with 
results available
132 133 126  
Result 4.06 (6.57) 0.24 (0.52) 0.07 (0.15) 25 (19) 18 (14) 80 (60) 91 (68) 72 (24)
LEV Number with 
results available
33 33 31  
Result 2.91 (7.71) 0.33 (0.60) 0.11 (0.19) 4 (12) 6 (18) 23 (70) 25 (76) 78 (48)
P value 0.864 0.502 0.695 0.357 0.580 0.411 0.411 0.123
Abbreviations: IQR, interquartile range; LEV, levetiracetam; MTX, methotrexate.
aPercentages for delayed elimination and delayed elimination at any time are based on the total population included in each group.
Figure 1. One minus cumulative event rate (time to nontoxic 
methotrexate concentration).
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Table 4. Comparison of Characteristics in Patients With Delayed Versus No Delayed Methotrexate Elimination.
Baseline Characteristic
Entire Population  
(n = 280)













(n = 116) P
Male, n (%) 57 (70) 132 (66) 0.513 34 (68) 63 (54) 0.101
Age, years, median (IQR) 49 (26) 56 (23) 0.003 49 (22) 57 (25) 0.005
Body surface area, m2, median (IQR) 1.99 (0.36) 1.92 (0.57) 0.267 2.03 (0.4) 1.98 (0.4) 0.012
Baseline creatinine clearance, mL/min, median (IQR) 97 (52) 85 (53) 0.301 101 (47) 77 (46) <0.001
Baseline AST, U/L, median (IQR) 19 (14) 21 (13) 0.382 15 (12) 21 (16) 0.140
Baseline ALT, U/L, median (IQR) 38 (24) 40 (26) 0.22 38 (27) 46 (46) 0.133
Diagnosis  
ALL 12 (15) 18 (9) 2 (4)  
Burkitt’s lymphoma 11 (14) 30 (15) 2 (4)  
CNS lymphoma 25 (31) 96 (48) 24 (48) 89 (77)  
Leptomeningeal carcinomatosis 1 (1) 13 (7) 1 (2)  
Mantle cell lymphoma 3 (4) 18 (9) 1 (1)  
NHL 17 (21) 2 (1) 13 (26) 12 (10)  
NHL (testicular) 1 (1) 14 (7) 6 (12) 14 (12)  
Osteosarcoma 6 (7) 8 (4) 2 (4)  
T-cell lymphoma 5 (6)  
Total methotrexate dose, mg, median (IQR) 5900 (5500) 6300 (5200) 0.012 7000 (2063) 7000 (1775) 0.855
Long methotrexate infusion time (22-24 hours), n 
(%)
31 (38) 83 (41) 0.569  
Number of interacting medications, n (%) 0.280 0.453
 0 70 (86) 156 (78) 42 (84) 93 (80)  
 1 8 (10) 34 (17) 5 (10) 19 (16)  
 2 3 (4) 9 (5) 3 (6) 4 (3)  
Pleural effusion, n (%) 0 (0) 1 (<1) 1 0 (0) 0 (0) 1
Ascites, n (%) 0 (0) 1 (<1) 1 0 (0) 1 (1) 1
Receiving levetiracetam, n (%) 8 (10) 25 (13) 0.527 8 (16) 25 (22) 0.411
Abbreviations: ALL, acute lymphoblastic leukemia; ALT, alanine transaminase; AST, aspartate transaminase; CNS, central nervous system; IQR, 
interquartile range; NHL, non-Hodgkin’s lymphoma.
levetiracetam is delayed when coadministered with pro-
benecid, and with this commonality, it is possible that the 2 
drugs compete for tubular secretion.8
Despite the potential for this drug-drug interaction, it 
was not observed in the current study. The only significant 
predictor of time to nontoxic methotrexate concentration 
and delayed elimination at any time was baseline creatinine 
clearance. Baseline characteristics between the groups were 
similar, besides those receiving levetiracetam being slightly 
older, with a higher baseline ALT, and more likely to be 
female. None of these discrepancies between groups are 
believed to have affected the results. These characteristics 
would have put the levetiracetam group at a disadvantage, 
leading to potentially higher incidences of delayed elimina-
tion in those receiving levetiracetam, which was not 
observed. Another difference noted between groups was in 
the median methotrexate concentration at 24 hours, which 
was higher in those not receiving levetiracetam when the 
entire population was analyzed. This discrepancy between 
groups was likely a result of the increased number of 
patients receiving prolonged infusions in the group without 
levetiracetam, which are typically associated with higher 
24-hour methotrexate concentrations.
Though the current study does not suggest the presence 
of an interaction, without a formal pharmacokinetic study, 
an interaction cannot be ruled out. It is possible that patients 
at risk for delayed elimination at baseline are at even higher 
risk when levetiracetam is present. In the adult case report 
described above, the patient had a slight delay in elimina-
tion in cycle 1, prior to starting levetiracetam. A slight delay 
in methotrexate elimination in those with other risk factors 
may be further enhanced in the presence of levetiracetam, 
which may not have been captured in the current study 
design. Although there was no significant difference 
between the groups, patients receiving levetiracetam did 
have a slightly higher incidence of delayed elimination at 
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any time (71% vs 76% in the entire population; 68% vs 76% 
in the bolus infusion population) and a slightly longer time 
to methotrexate concentration <0.1 µmol/L (72 vs 78 hours 
in both the entire population and the bolus infusion popula-
tion). These slight differences could be significant to a 
patient with additional risk factors for delayed elimination. 
Additionally, this study did not record the incidence of 
adverse events; therefore, it is possible that patients receiv-
ing concomitant levetiracetam had a higher frequency of 
adverse events despite insignificant changes in methotrex-
ate elimination. However, this is unlikely because of the 
strong correlation between methotrexate serum concentra-
tions and the rate of adverse events.3 This study was limited 
by the retrospective nature and limited number of patients 
receiving levetiracetam concomitantly with methotrexate.
Conclusion
This study did not detect a difference in methotrexate elimi-
nation caused by coadministration of levetiracetam and 
methotrexate and refutes the hypothesis generated by the 2 
case reports; however, one of the cases included a dose of 
12 g/m2, whereas the other included a dose of 5 g/m2. In this 
study, the median dose was 3.5 g/m2. Delayed elimination 
caused by concomitant levetiracetam administration cannot 
be completely ruled out without a prospective, controlled, 
formal pharmacokinetic analysis; however, a clinically sig-
nificant interaction is unlikely in those without additional 
risk factors for delayed elimination.
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